MRK vs TMO
MRK: Merck & Co. is a leading global biopharmaceutical firm dedicated to delivering life-saving vaccines and innovative therapeutic medicines for major disease areas. TMO: A massive, diversified life sciences conglomerate providing the essential infrastructure, tools, and services that enable scientific research and global healthcare diagnostics.
Side-by-side fundamentals
| Metric | MRK | TMO | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $150.66 | $628.74 | |
| Market cap as of 2026-08-24 | $371.7B | $232.5B | |
| P/E as of 2026-08-24 | 120.33 | 33.85 | TMO lower |
| PEG as of 2026-08-24 | 4.91 | 3.39 | TMO lower |
| Net margin as of 2026-08-24 | +4.8% | +15.0% | TMO higher |
| Gross margin as of 2026-08-24 | +77.3% | +40.9% | MRK higher |
| Operating margin as of 2026-08-24 | +9.6% | +17.6% | TMO higher |
| ROE as of 2026-08-24 | +17.9% | +13.3% | MRK higher |
| ROA as of 2026-08-24 | +7.0% | +6.3% | MRK higher |
| Debt / equity as of 2026-08-24 | 1.07 | 0.81 | TMO lower |
| Revenue growth (YoY) as of 2026-08-24 | +4.6% | +7.2% | TMO higher |
| Revenue CAGR (3y) SEC XBRL | +3.1% | -0.3% | MRK higher |
| Dividend yield as of 2026-08-24 | +2.9% | +0.3% | MRK higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-08-24 | 0.28 | 0.76 | |
| 1-year return as of 2026-08-24 close | +72.4% | +25.8% | MRK higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.